With the first chimeric antigen receptor T-cell (CAR-T) therapies on the market and making headway, the next wave of development is advancing, with next-generation technologies including allogeneic therapies and CAR-T cells with an on/off switch looking to take the stage.
CAR-T Forecast: Celgene Follows, But Also Leads As Next Batch Of T-Cell Therapies Near Market
Celgene's lead program will be the third autologous CD19-targeting T-cell therapy on the market, but the company is in the lead among BCMA-targeting CAR-T candidates. Next-generation technologies are also on the way.
More from Immuno-oncology
• By
Increasingly focused on maximizing and accelerating the progress of its PD-L1 x VEGF inhibitor BNT357, the company expects new partnerships to be announced this year.
• By
Sun is acquiring Checkpoint Therapeutics, opening up opportunities to build out its strategy in the onco-derm segment with the US firm’s FDA-approved anti-PD-L1 mAb.
• By
The MATTERHORN study could set Imfinzi up for another new perioperative use, even though the gastric cancer trial has yet to demonstrate an overall survival benefit.
• By
Summit and Akeso have established a big lead in lung cancer with ivonescimab, but BioNTech aims to make its rival, BNT327, the leader in other tumor types.
More from Anticancer
• By
The acquisition is worth up to $1bn and adds to AstraZeneca’s broad array of cell therapy technologies.
• By
The Singapore and Seattle-based biotech is joining the race to bring a ‘double whammy’ antibody-drug conjugate to patients.
• By
A Phase III trial testing the protein degrader in breast cancer met the primary endpoint and showed an efficacy benefit only in the subgroup of ESR1 mutant patients, not the full population.